REPROCELL Brand
Bioserve®
Unparalleled Access to Human Biospecimens
We have supplied human tissue samples to nearly every major pharmaceutical and biotechnology company, as well as top industry, academic, and government research institutions.
We also provide a full range of accurate and cost-effective preclinical molecular services.
Human Tissue Samples
The REPROCELL Bioserve global biorepository of human tissue samples provides leading academic and industry researchers with access to over 600,000 human DNA, serum and tissue samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients on four continents.
If we do not have what you're looking for in our biorepository, then through our biospecimen partner network of affiliated hospitals we can initiate a prospective sample collection specific to you.
Preclinical Genomic Services
REPROCELL Bioserve's genomic services complement our global biorepository of human tissue samples.
We offer our nucleic acid extraction, RT-PCR (qPCR), Next Generation Sequencing (NGS), and biomarker services for any project, for helping researchers identify genetic markers, validate drug targets and correlate clinical and molecular data to accelerate the development of new and safer drugs.
We specialize in smaller to mid-size projects, providing intensive customer service from assay design to data delivery and discussion with you about your experiment results.
Oligonucleotide Synthesis
Bioserve India (India's largest oligosynthesis provider) is now offering its services globally, with a complete line of custom oligonucleotide synthesis and purification services based on customer requirements, including:
- Long Mer oligos – up to 150 bases, single or double stranded.
- Modified oligos – besides standard modifications, fluorescent, non-fluorescent, and q-PCR probes are available.
- NGS Grade oligos – manufactured by proprietary methods that are proven to reduce index cross-talk and increase the success of multiplex NGS experiments.
- Universal Primer – complementary nucleotide sequences designed to bind to a wide variety of DNA templates for amplifying very similar genes found in species of the same genus.
Oligos are synthesised to a very high quality, at scales up to 10,000 nanomole, with a wide range of purification techniques to suit your requirements.
The History of Bioserve
The Bioserve brand of REPROCELL has it origin dating back to 1990. Bioserve was originally founded as an independent company with a business model to establish a commercial biorepository of human clinical samples to support basic research and drug discovery. Acquired by REPROCELL in 2014, Bioserve offices have since become the headquarters of REPROCELL USA, located in Beltsville, MD.
As one of the world’s largest commercial biorepositories of human specimens, under the Bioserve brand, the organization also offers a full suite of preclinical molecular services.
Timeline
2011 – present
2015 – Bioserve offices become REPROCELL USA division headquarters
2014 – Bioserve is acquired by REPROCELL, Inc. (Japan)
2012 – The Ventyx Wesley Research Institute Tissue Bank joins the Bioserve Network
2001 – 2010
2010 – Bioserve Europe founded in August: formed Bioserve Network
2009 – Upgraded current facility laboratory space to current 21,000 sq.ft. footprint
2007 – Acquired and assets of Genomics Collaborative, Inc. from SeraCare
2007 – Relocated Bioserve to Beltsville, Maryland facility
2007 – Obtained CLIA certification
2006 – Expanded HTP genotyping capabilities with Sequenom iPlex platform
2006 – Bioserve India relocates to expanded laboratory facility (14,000 sq.ft.)
2003 – Acquired assets of Qiagenomics in Seattle, Washington
2002 – Bioserve India founded in Hyderabad, India
2001 – Integrated HTP genotyping into services offering (Sequenom technology)
2001 – Bioserve renews multiyear contract with NIEHS
1989 – 2000
2000 – Bioserve presents 3 abstracts and mini-seminar on p53 at AACR in Philadelphia
1998 – Bioserve integrates realtime PCR platform (ABI) into services offering
1997 – Bioserve upgrades to high-through-put DNA synthesizer platforms
1996 – Laboratory space expanded from 5,000 sq.ft. to 12,000 sq.ft.
1995 – Bioserve secures multi-year contract with NIEHS
1994 – Bioserve secures SBIR grants for genetic analysis in prostate cancers
1993 – Bioserve secures SBIR grants for sub-typing HPV in oral cancers
1992 – Bioserve “graduates” from TAP and re-locates to facility in Laurel, Maryland
1991 – Bioserve secures first blanket purchase order agreement with NIH
1990 – Bioserve officially incorporated as a business on January 5
1989 – Bioserve founded (Oct.7) by NCI researchers with funding from Univ. of Maryland TAP